Drug Trial News

RSS

OPKO Health acquires Cytochroma

OPKO Health, Inc. announced that it has completed the acquisition of Cytochroma Inc. Cytochroma's lead products include CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, and Fermagate Tablets, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in CKD patients on chronic hemodialysis.

4 Mar 2013

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

4 Mar 2013

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.

4 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

KYTHERA Biopharmaceuticals, Inc. today announced four abstracts will be presented at the 71st American Academy of Dermatology (AAD) Annual Meeting in Miami Beach, Fla.

2 Mar 2013

Nationwide clinical drug trials give hope for patients with autism and fragile X syndrome

As scientists uncover the precise links between autism and the fragile x gene, potential treatments to reverse many of the core symptoms of both autism and fragile X syndrome (FXS) are moving closer to reality.

2 Mar 2013

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).

1 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

1 Mar 2013

Griffith University's Institute for Glycomics launches human trials for Streptococcus A vaccine

Griffith University's Institute for Glycomics has launched human trials for a vaccine against Streptococcus A, the germ that causes rheumatic fever.

1 Mar 2013

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Anacor Pharmaceuticals today announced positive preliminary results from the second of two Phase 3 trials of tavaborole (known as Study 302).

28 Feb 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine.

28 Feb 2013

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA.

28 Feb 2013

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Takeda Pharmaceutical Company Limited and Resolve Therapeutics, LLC today jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus (also known as Systemic Lupus Erythematosus, or SLE) and other autoimmune diseases.

27 Feb 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

Omega-3 fish oils could help protect against skin cancer

Taking omega-3 fish oils could help to protect against skin cancer, according to researchers at The University of Manchester.

27 Feb 2013

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC.

26 Feb 2013

Drug Trial News

OPKO Health acquires Cytochroma

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

Nationwide clinical drug trials give hope for patients with autism and fragile X syndrome

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Oraya Therapy safe and effective for patients with wet AMD

Griffith University's Institute for Glycomics launches human trials for Streptococcus A vaccine

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Resolve Therapeutics, Takeda partner to develop compounds for treatment of lupus

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Ampio Pharmaceuticals starts Optina clinical trial

Omega-3 fish oils could help protect against skin cancer

High-level results from AstraZeneca’s naloxegol Phase III trial on opioid-induced constipation

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News